Research graph
References from Memantine in Korean Alzheimer’s disease: A prospective real-world REMIND study. Local targets link to admitted publications; unresolved targets remain external evidence.
Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019
10.1016/s2468-2667(21)00249-8 · 2022 · External reference
Prevalence and incidence of dementia in South Korea: a nationwide analysis of the National Health Insurance Service Senior Cohort
10.3988/jcn.2021.17.2.249 · 2021 · External reference
Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial
10.1001/jama.2023.13239 · 2023 · External reference
Lecanemab in early Alzheimer’s disease
10.1056/nejmoa2212948 · 2023 · External reference
Eligibility for lecanemab treatment in the Republic of Korea: real-world data from memory clinics
10.3988/jcn.2024.0550 · 2025 · External reference
Eligibility for lecanemab and donanemab in Korea under Appropriate Use Recommendations
10.1002/alz.70875 · 2025 · External reference
The effects of memantine on behavioral disturbances in patients with Alzheimer’s disease: a meta-analysis
10.2147/ndt.s142839 · 2017 · External reference
Memantine for dementia
2019 · External reference
Memantine in moderate-to-severe Alzheimer’s disease
10.1056/nejmoa013128 · 2003 · External reference
Dynamic associations of cholinesterase inhibitors and memantine with cognitive trajectories in individuals with Alzheimer’s or mixed dementia: a real-world analysis using the quality registry SveDem
10.1186/s13195-025-01918-0 · 2025 · External reference
Memantine therapy for Alzheimer disease in real-world practice: an observational study in a large representative sample of French patients
10.1097/wad.0b013e31815a9e10 · 2008 · External reference
A multicentre, randomised, open-label, prospective study to estimate the add-on effects of memantine as Ebixa® oral pump (solution) on language in patients with moderate to severe Alzheimer’s disease already receiving donepezil (ROMEO-AD)
10.1007/s40120-023-00494-5 · 2023 · External reference
Unresolved reference
1992 · External reference
Prognosis of Alzheimer’s disease today: a two-year prospective study in 686 patients from the REAL-FR Study
10.1016/j.jalz.2007.10.018 · 2008 · External reference
Real-world effectiveness, its predictors and onset of action of cholinesterase inhibitors and memantine in dementia: retrospective health record study
10.1192/bjp.2020.136 · 2021 · External reference
Evaluation of clinical benefits of treatments for Alzheimer’s disease
10.1016/s2666-7568(23)00193-9 · 2023 · External reference
Clinically meaningful outcomes in Alzheimer’s disease and Alzheimer’s disease related dementias trials
2025 · External reference
Memantine monotherapy for Alzheimer’s disease: a systematic review and meta-analysis
10.1371/journal.pone.0123289 · 2015 · External reference
Memantine MEM-MD-02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment
10.1212/01.wnl.0000223333.42368.f1 · 2006 · External reference
Donepezil and memantine for moderate-to-severe Alzheimer’s disease
10.1056/nejmoa1106668 · 2012 · External reference
Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist—a review of preclinical data
10.1016/s0028-3908(99)00019-2 · 1999 · External reference
Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders
10.1038/nrn2911 · 2010 · External reference
Quality of life and caregiver burden of Alzheimer’s disease among community dwelling patients in Europe: variation by disease severity and progression
10.3233/adr-210025 · 2021 · External reference
Three-year trajectories of caregiver burden in Alzheimer’s disease
10.3233/jad-140360 · 2014 · External reference
Reliability, validity and reference values of the Zarit Burden Interview for assessing informal caregivers of community-dwelling older persons with dementia
10.1017/s0714980800012484 · 2000 · External reference
Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy
10.1097/00004850-200303000-00003 · 2003 · External reference
A real-world analysis of treatment patterns for cholinesterase inhibitors and memantine among newly-diagnosed Alzheimer’s disease patients
10.1007/s40120-017-0067-7 · 2017 · External reference
Real-world use of symptomatic treatments in early Alzheimer’s disease
10.3233/jad-220471 · 2023 · External reference
